Acorda Therapeutics, Inc.
ACORDelisted Apr 25, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001008848
Acorda Therapeutics, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Jun 23, 2023; 17 institutions reported holding it in 13F filings for Q1 2024, worth $2.13M in total; no superinvestor held it.
Q2 2023 vs. Q1 2023
How the institutions holding Acorda Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 30 | 1 | 15 | −14 |
| SharesConverted for a 1-for-20 split | 325.1K | 90.2K | 149.4K | −85.6K (−36.4%) |
| Value | $3.71M | $1.01M | $1.94M | −$757.1K (−28.1%) |
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Acorda Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| FMR LLC | 1 | $13 | 0.00% |
Sold out (15)
Institutions that held Acorda Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 218,830 | $128.2K |
| Millennium Management LLC | 174,483 | $102.0K |
| Vanguard Group Inc | 159,778 | $93.6K |
| Two Sigma Securities, LLC | 141,152 | $82.7K |
| Bridgeway Capital Management, LLC | 76,706 | $45.0K |
| Geode Capital Management, LLC | 66,693 | $39.1K |
| HN Saltoro Capital, LP | 51,391 | $23.9K |
| Northern Trust Corp | 39,114 | $22.9K |
| State Street Corp | 31,648 | $18.5K |
| Two Sigma Investments, LP | 27,082 | $15.9K |
| Simplex Trading, LLC | 15,416 | $9.00K |
| Two Sigma Advisers, LP | 14,700 | $8.61K |
| Simon Quick Advisors, LLC | 14,370 | $8.42K |
| HRT Financial LP | 12,520 | $7.00K |
| UBS Group AG | 6,025 | $3.53K |
Not filed for Q2 2023 yet (1)
Institutions that held Acorda Therapeutics, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Davidson Kempner Partners | 1,803,070 | $1.01M |